XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTLB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
xtlb · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for XTL Biopharmaceuticals Ltd. (XTLB) measures how much investors pay for each dollar of the company's trailing earnings. XTLB's current PE ratio of N/A is calculated by dividing its stock price of $2.23 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%0.2x
MedianQ3 · 75%2.1x
Max
At N/A, XTLB's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
XTL Biopharmaceuticals Ltd.You XTLB | $5M | N/A | — | -$0.00 |
 AIM ImmunoTech Inc. AIM | $2M | N/A | — | -$8.62 |
 Cyclerion Therapeutics, Inc. CYCN | $13M | N/A | — | -$1.09 |
 Ensysce Biosciences, Inc. ENSC | $2M | N/A | — | -$3.98 |
 KALA BIO, Inc. KALA | $50M | N/A | — | -$3.31 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 Polyrizon Ltd. PLRZ | $14M | N/A | — | -$2.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-9.77 | — | |
2023-12-31 FY2023 | — | $-0.02 | — | |
2022-12-31 FY2022 | — | $-15.83 | — | |
2021-12-31 FY2021 | 2.12x | $5.23 | — | |
2020-12-31 FY2020 | — | $-9.73 | — | |
2019-12-31 FY2019 | — | $-16.77 | — | |
2018-12-31 FY2018 | 0.19x | $37.16 | — | |
2017-12-31 FY2017 | — | $-10.63 | — | |
2016-12-31 FY2016 | — | $-59.44 | — | |
2015-12-31 FY2015 | — | $-104.62 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for XTL Biopharmaceuticals Ltd. (XTLB) measures how much investors pay for each dollar of the company's trailing earnings. XTLB's current PE ratio of N/A is calculated by dividing its stock price of $2.23 by its TTM earnings per share of -$0.00.
Frequently asked questions
XTLB pe ratio · 6 questionsXTLB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.23 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via XTLB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · XTL Biopharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09